{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T18:32:11Z","timestamp":1775327531173,"version":"3.50.1"},"reference-count":32,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2020]]},"DOI":"10.3960\/jslrt.20041","type":"journal-article","created":{"date-parts":[[2020,11,3]],"date-time":"2020-11-03T22:09:23Z","timestamp":1604441363000},"page":"159-168","source":"Crossref","is-referenced-by-count":15,"title":["Clinicopathological evaluation of methotrexate-associated                    lymphoproliferative disorders with special focus on Epstein-Barr virus-positive                    mucocutaneous lesions"],"prefix":"10.3960","volume":"60","author":[{"given":"Sawako","family":"Shiraiwa","sequence":"first","affiliation":[{"name":"Department of Pathology, Tokai University,                    School of Medicine, Isehara,                    Japan,"},{"name":"Department of Hematology                    and Oncology, Tokai University, School of                    Medicine, Isehara,                Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yara Yukie","family":"Kikuti","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tokai University,                    School of Medicine, Isehara,                    Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joaquim","family":"Carreras","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tokai University,                    School of Medicine, Isehara,                    Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryujiro","family":"Hara","sequence":"additional","affiliation":[{"name":"Department of Hematology                    and Oncology, Tokai University, School of                    Medicine, Isehara,                Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuyuki","family":"Aoyama","sequence":"additional","affiliation":[{"name":"Department of Hematology                    and Oncology, Tokai University, School of                    Medicine, Isehara,                Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daisuke","family":"Ogiya","sequence":"additional","affiliation":[{"name":"Department of Hematology                    and Oncology, Tokai University, School of                    Medicine, Isehara,                Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rikio","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Hematology                    and Oncology, Tokai University, School of                    Medicine, Isehara,                Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masako","family":"Toyosaki","sequence":"additional","affiliation":[{"name":"Department of Hematology                    and Oncology, Tokai University, School of                    Medicine, Isehara,                Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ken","family":"Ohmachi","sequence":"additional","affiliation":[{"name":"Department of Hematology                    and Oncology, Tokai University, School of                    Medicine, Isehara,                Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshiaki","family":"Ogawa","sequence":"additional","affiliation":[{"name":"Department of Hematology                    and Oncology, Tokai University, School of                    Medicine, Isehara,                Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kawada","sequence":"additional","affiliation":[{"name":"Department of Hematology                    and Oncology, Tokai University, School of                    Medicine, Isehara,                Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinji","family":"Sato","sequence":"additional","affiliation":[{"name":"Department of                    Rheumatology, Tokai University School of                    Medicine, Isehara,                Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoya","family":"Nakamura","sequence":"additional","affiliation":[{"name":"Department of Pathology, Tokai University,                    School of Medicine, Isehara,                    Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kiyoshi","family":"Ando","sequence":"additional","affiliation":[{"name":"Department of Hematology                    and Oncology, Tokai University, School of                    Medicine, Isehara,                Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","unstructured":"1 Ellman MH, Hurwitz H, Thomas C, Kozloff M.                        Lymphoma developing in a patient with rheumatoid arthritis                        taking low dose weekly methotrexate.                    J Rheumatol.                    1991; 18 :                    1741-1743."},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Swerdlow SH, Campo E, Pileri SA <i>et al.<\/i>                    The 2016 revision of the World Health Organization classification                        of lymphoid neoplasms.                    Blood.                    2016; 127 :                        2375-2390.","DOI":"10.1182\/blood-2016-01-643569"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Kameda H, Fujii T, Nakajima A <i>et al.<\/i>                    Japan College of Rheumatology guideline for the use of                        methotrexate in patients with rheumatoid arthritis.                    Mod Rheumatol.                    2019; 29 :                    31-40.","DOI":"10.1080\/14397595.2018.1472358"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4 Baecklund E, Iliadou A, Askling J <i>et al.<\/i>                    Association of chronic inflammation, not its treatment, with                        increased lymphoma risk in rheumatoid arthritis.                    Arthritis Rheum.                    2006; 54 :                    692-701.","DOI":"10.1002\/art.21675"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Baecklund E, Sundstr\u00f6m C, Ekbom A <i>et al.<\/i>                    Lymphoma subtypes in patients with rheumatoid arthritis:                        increased proportion of diffuse large B cell lymphoma.                    Arthritis Rheum.                    2003; 48 :                    1543-1550.","DOI":"10.1002\/art.11144"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 Kojima M, Itoh H, Hirabayashi K <i>et al.<\/i>                    Methtrexate-associated lymphoproliferative disorders. A                        clinicopathological study of 13 Japanese cases.                    Pathol Res Pract.                    2006; 202 :                    679-685.","DOI":"10.1016\/j.prp.2006.05.007"},{"key":"7","unstructured":"7 Bleyer WA.                        Methotrexate induced lymphoma?                    J Rheumatol.                    1998; 25 :                    404-407."},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Hashimoto A, Chiba N, Tsuno H <i>et al.<\/i>                    Incidence of malignancy and the risk of lymphoma in Japanese                        patients with rheumatoid arthritis compared to the general                        population.                    J Rheumatol.                    2015; 42 :                    564-571.","DOI":"10.3899\/jrheum.140533"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Kameda T, Dobashi H, Miyatake N <i>et al.<\/i>                    Association of higher methotrexate dose with lymphoproliferative                        disease onset in rheumatoid arthritis patients.                    Arthritis Care Res.                    2014; 66 :                    1302-1309.","DOI":"10.1002\/acr.22306"},{"key":"10","unstructured":"10 Hoshida Y, Xu JX, Fujita S <i>et al.<\/i>                    Lymphoproliferative disorders in rheumatoid arthritis:                        clinicopathological analysis of 76 cases in relation to methotrexate                        medication.                    J Rheumatol.                    2007; 34 :                    322-331."},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Tokuhira M, Tamaru J, Kizaki M.                        Clinical management for other iatrogenic                        immunodeficiency-associated lymphoproliferative disorders.                    J Clin Exp Hematop.                    2019; 59 :                    72-92.","DOI":"10.3960\/jslrt.19007"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Hellgren K, Baecklund E, Backlin C <i>et al.<\/i>                    Rheumatoid arthritis and risk of malignant lymphoma: is the risk                        still increased?                    Arthritis Rheumatol.                    2017; 69 :                    700-708.","DOI":"10.1002\/art.40017"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Gion Y, Iwaki N, Takata K <i>et al.<\/i>                    Clinicopathological analysis of methotrexate-associated                        lymphoproliferative disorders: comparison of diffuse large B-cell lymphoma                        and classical Hodgkin lymphoma types.                    Cancer Sci.                    2017; 108 :                        1271-1280.","DOI":"10.1111\/cas.13249"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Kamel OW, Weiss LM, van                                de                        Rijn M <i>et al.<\/i>                    Hodgkin\u2019s disease and lymphoproliferations resembling                        Hodgkin\u2019s disease in patients receiving long-term low-dose                        methotrexate therapy.                    Am J Surg Pathol.                    1996; 20 :                    1279-1287.","DOI":"10.1097\/00000478-199610000-00015"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Dojcinov SD, Venkataraman G, Raffeld M, Pittaluga S, Jaffe ES.                        EBV positive mucocutaneous ulcer\u2014a study of 26 cases                        associated with various sources of immunosuppression.                    Am J Surg Pathol.                    2010; 34 :                    405-417.","DOI":"10.1097\/PAS.0b013e3181cf8622"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Ikeda T, Gion Y, Yoshino T, Sato Y.                    A review of EBV-positive mucocutaneous ulcers focusing on                        clinical and pathological aspects.                    J Clin Exp Hematop.                    2019; 59 :                    64-71.","DOI":"10.3960\/jslrt.18039"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Ikeda T, Gion Y, Sakamoto M <i>et al.<\/i>                    Clinicopathological analysis of 34 Japanese patients with                        EBV-positive mucocutaneous ulcer.                    Mod Pathol.                    2020 June 19. DOI: . [Online ahead of                        print]","DOI":"10.1038\/s41379-020-0599-8"},{"key":"18","unstructured":"18 Ishida M, Hodohara K, Yoshii M <i>et al.<\/i>                    Methotrexate-related Epstein-Barr virus-associated                        lymphoproliferative disorder occurring in the gingiva of a patient with                        rheumatoid arthritis.                    Int J Clin Exp Pathol.                    2013; 6 :                    2237-2241."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Daroontum T, Kohno K, Eladl AE <i>et al.<\/i>                    Comparison of Epstein-Barr virus-positive mucocutaneous ulcer                        associated with treated lymphoma or methotrexate in Japan.                    Histopathology.                    2018; 72 :                    1115-1127.","DOI":"10.1111\/his.13464"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Kurita D, Miyoshi H, Ichikawa A <i>et al.<\/i>                    Methotrexate-associated lymphoproliferative disorders in patients                        with rheumatoid arthritis: clinicopathologic features and prognostic                        factors.                    Am J Surg Pathol.                    2019; 43 :                    869-884.","DOI":"10.1097\/PAS.0000000000001271"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Attard AA, Praveen P, Dunn PJS, James GJ.                        Epstein-Barr virus\u2013positive mucocutaneous ulcer of the                        oral cavity: the importance of having a detailed clinical history to reach a                        correct diagnosis.                    Oral Surg Oral Med Oral Pathol Oral Radiol.                    2012; 114 :                    e37-e39.","DOI":"10.1016\/j.oooo.2012.04.003"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Sigmundsdottir H, Johnston A, Gudjonsson JE, Bjarnason B, Valdimarsson H.                        Methotrexate markedly reduces the expression of vascular                        E-selectin, cutaneous lymphocyte-associated antigen and the numbers of                        mononuclear leucocytes in psoriatic skin.                    Exp Dermatol.                    2004; 13 :                    426-434.","DOI":"10.1111\/j.0906-6705.2004.00177.x"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23 Ichikawa A, Arakawa F, Kiyasu J <i>et al.<\/i>                    Methotrexate\/iatrogenic lymphoproliferative disorders in                        rheumatoid arthritis: histology, Epstein-Barr virus, and clonality are                        important predictors of disease progression and regression.                    Eur J Haematol.                    2013; 91 :                    20-28.","DOI":"10.1111\/ejh.12116"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24 Feng W, Cohen JI, Fischer S <i>et al.<\/i>                    Reactivation of latent Epstein-Barr virus by methotrexate: a                        potential contributor to methotrexate-associated lymphomas.                    J Natl Cancer Inst.                    2004; 96 :                    1691-1702.","DOI":"10.1093\/jnci\/djh313"},{"key":"25","unstructured":"25 Srivastava AK, Shukla S, Srivastava P <i>et al.<\/i>                    Real time detection and quantification of Epstein-Barr virus in                        different grades of oral gingivitis and periodontitis                        patients.                    J Exp Ther Oncol.                    2019; 13 :                    9-14."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26 Hern\u00e1di K, Szalm\u00e1s A, Mogyor\u00f3si R <i>et al.<\/i>                    Prevalence and activity of Epstein-Barr virus and human                        cytomegalovirus in symptomatic and asymptomatic apical periodontitis                        lesions.                    J Endod.                    2010; 36 :                    1485-1489.","DOI":"10.1016\/j.joen.2010.06.008"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27 Moriya K, Kikuti YY, Carreras J <i>et al.<\/i>                    Methotrexate-associated lymphoproliferative disorder                        demonstrating composite lymphoma of EBV-negative diffuse large B-cell                        lymphoma and EBV-positive mucocutaneous ulcer.                    J Clin Exp Hematop.                    2020; 60 :                    11-16.","DOI":"10.3960\/jslrt.19038"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28 Heslop HE.                        Biology and treatment of Epstein-Barr virus-associated                        non-Hodgkin lymphomas.                    Hematology Am Soc Hematol Educ Program.                    2005; 2005 :                    260-266.","DOI":"10.1182\/asheducation-2005.1.260"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29 Yamakawa N, Fujimoto M, Kawabata D <i>et al.<\/i>                    A clinical, pathological, and genetic characterization of                        methotrexate-associated lymphoproliferative disorders.                    J Rheumatol.                    2014; 41 :                    293-299.","DOI":"10.3899\/jrheum.130270"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30 Tokuhira M, Tanaka Y, Takahashi Y <i>et al.<\/i>                    The clinical impact of absolute lymphocyte count in peripheral                        blood among patients with methotrexate - associated lymphoproliferative                        disorders.                    J Clin Exp Hematop.                    2020; 60 :                    41-50.","DOI":"10.3960\/jslrt.19039"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31 Inui Y, Matsuoka H, Yakushijin K <i>et al.<\/i>                    Methotrexate-associated lymphoproliferative disorders: management                        by watchful waiting and observation of early lymphocyte recovery after                        methotrexate withdrawal.                    Leuk Lymphoma.                    2015; 56 :                    3045-3051.","DOI":"10.3109\/10428194.2015.1022769"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32 Saito S, Kaneko Y, Yamaoka K, Tokuhira M, Takeuchi T.                        Distinct patterns of lymphocyte count transition in                        lymphoproliferative disorder in patients with rheumatoid arthritis treated                        with methotrexate.                    Rheumatology (Oxford). 2017; 56 :                        940-946.","DOI":"10.1093\/rheumatology\/kex002"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/60\/4\/60_20041\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,12,19]],"date-time":"2020-12-19T04:36:15Z","timestamp":1608352575000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/60\/4\/60_20041\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":32,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2020]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.20041","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020]]}}}